Exdensur (depemokimab) — Clinical data readout
in 2026
Further pivotal readouts expected in 2026: camlipixant (chronic cough); Jemperli (rectal cancer); 3x yearly (Q4M) HIV PrEP; and Exdensur for EGPASource filing
GSK biotech catalysts & pipeline
GSK PLC · Data as of 2026-10-25
Upcoming catalysts
Jideytro (zidesamtinib) — NDA/BLA submission
2026
The data were presented in a Presidential Symposium session at the 2026 World Conference on Lung Cancer (WCLC) in Seoul, South Korea, and will support a planned supplemental New Drug Application to the US FDA this year to expand the indication for Jideytro to include first-line treatment.Source filing
neladalkib — PDUFA
Nov 27
The company is advancing additional medicines from the recent Nuvalent acquisition, including neladalkib (NVL-655) for patients with ALK-altered NSCLC, which is currently under FDA review with a target decision date of 27 November 2026, and NVL-330, an investigational treatment for HER2-altered NSCLC.Source filing
Arexvy — Regulatory decision
2027
A regulatory decision is expected in 2027.Source filing
ozureprubart — Clinical data readout
2027
Data from the phase IIb trial (prestIgE) assessing use of ozureprubart as monotherapy is expected in 2027, with phase III trials to be focused on both at-risk adult and paediatric populations.Source filing
risvutatug rezetecan — Clinical data readout
2027
GSK holds exclusive rights to develop and commercialise Ris-Rez outside mainland China, Hong Kong, Macau and Taiwan, and is advancing a broad global clinical development programme across lung cancer, prostate cancer and other solid tumours, including the phase III EMBOLD SCLC-301 trial in relapsed extensive-stage SCLC, with pivotal data expected next year.Source filing
Blenrep (belantamab mafodotin) — Interim data
early 2028
Interim efficacy and safety data for Blenrep as a first line treatment are expected in early 2028 with enrolment expanded to US sites to increase US patient representation in the study population.Source filing
Jemperli (dostarlimab) — Conference presentation
Oct 23–Oct 27
Full data from the AZUR-1 interim analysis will be presented at the European Society for Medical Oncology (ESMO) Congress in October 2026.Source filing
risvutatug rezetecan — Conference presentation
Oct 23–Oct 27
These findings will be presented in a poster session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain.Source filing